ClinicalTrials.gov
public full text
Public Domain
Pembrolizumab and Olaparib in Cervical Cancer Patients
The study is a non-randomized, open-label phase II clinical trial to test the investigational combination of the drug pembrolizumab with the drug olaparib in patients diagnosed with advanced or recurrent cervical carcinoma after standard chemotherapy.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)#353417
- A Trial for Patients With Advanced/Recurrent Cervical Cancer#830015
- Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer#834513
- SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer#226267
- VMAT Concurrent Cisplatin Plus Nab-paclitaxel for Local Advanced Cervical Cancer#907420
Record · ID 878256
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive